Complaion raises €13.5M Seed to automate compliance documentation for regulated industries

Complaion (Milan) has raised €13.5 million in a Seed round. The company builds an AI-powered platform that automates compliance documentation and regulatory workflows for companies operating in life sciences, medical devices, and manufacturing — industries where documentation errors carry direct regulatory and commercial consequences.

What Complaion does

The platform addresses the documentation burden that surrounds regulatory submissions in highly regulated industries. In medical devices, for instance, a CE mark application under EU MDR requires a structured technical file that maps the device's design, manufacturing process, clinical data, and post-market surveillance plan against specific regulatory requirements. In pharmaceuticals, IND and NDA submissions demand analogous structured evidence packages.

Complaion's system is designed to map an organisation's existing documentation against the requirements of the relevant regulatory framework, identify gaps, and assist in generating the structured documentation needed to close them. The platform covers EU MDR (medical devices), ISO 13485 (quality management for medical devices), FDA 21 CFR Part 11 (electronic records), and adjacent frameworks across the life sciences and industrial manufacturing space.

The compliance documentation market

The market for regulatory affairs software in life sciences is established but fragmented. The legacy players — Veeva Vault, MasterControl, and document management systems adapted for GxP compliance — are deeply embedded in large pharmaceutical and medical device companies, but their workflows are built around document storage and audit trails rather than AI-assisted content generation or gap analysis.

The AI layer Complaion is building targets the pre-submission phase: the period when a regulatory team is assembling a dossier and needs to identify missing evidence, inconsistent claims, or structural gaps before an external review surfaces them. That workflow is currently manual and consultant-intensive, which creates the opening for a platform that can automate the analysis and flag issues earlier in the process.

Capital from the round will fund platform expansion across European regulated industries and growth in the engineering and commercial teams. The investor syndicate was not disclosed.